BioIVT to Highlight Research Advances Made Using its Hepatocyte Products and Services at the 12th International ISSX Meeting

Westbury, NY – July 23, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting. This conference will be held from July 28-31 at the Oregon Convention Center in Portland, OR.

“We are excited to have this opportunity to showcase some of the research advances being made using our hepatic products and research services. They span research areas as diverse as investigating the impact of HIV integrase inhibitor drugs on folate transporters and the potential for clinically-relevant botanical-drug interactions (BDIs) with Boswellia serrata, which is used as an anti-inflammatory supplement,” said Dr. Chris Black, BioIVT Senior Vice President ADME-TOX. “BioIVT is a leader in developing in vitro hepatic modeling solutions and we are delighted to share our knowledge and experience with our peers.”

During a BioIVT-sponsored symposium, Amy L. Roe, PhD, DABT, Principal Toxicologist, Product Safety & Regulatory Affairs at The Procter and Gamble Company, will discuss a published BDI study (Roe et. al., 2019 AIVT) that she conducted with BioIVT Vice President - ADME-TOX Dr. Kenneth R. Brouwer and other BioIVT researchers. Their work compared two in vitro methods – conventional pooled human liver microsomes and a more physiologically-relevant sandwich-cultured human hepatocytes (SCHH) model – to evaluate the inhibitory effects of B. serrata on CYP enzymatic activity. CYP enzymes play an important role in drug metabolism, so inhibiting them can change the effectiveness and safety of some drugs.

This work is particularly important because the use of botanical supplements is highest amongst the elderly, who are more likely to have comorbidities and take multiple medications. SCHH is an effective model for studying complex mixtures and can be used to evaluate both BDIs and drug-drug interactions. Entitled “Potential Benefits of a Physiologically-relevant Whole Cell Model to Assess CYP Inhibition with Complex Mixtures,” this session will be held from 5:30-6:30 p.m. on Tuesday, July 30.

BioIVT will also play an active role in the 15th annual assembly of the Hepatocyte Research Association (HRA), which will provide “Perspectives on Comparisons of Different In Vitro Hepatic Models,” from 5:30-9 p.m. on Monday, July 29. Interested parties can register for this meeting at

In addition, several of BioIVT’s recent research projects will be highlighted in poster format, as follows:

Monday, 29 July

11:00 a.m. – 1 p.m.

  • P35: The Use of Primary Cryopreserved Human Hepatocytes as a Model for Non-Alcoholic Fatty Liver Disease (NAFLD) Related Changes In Phase I And Phase II Enzyme Activities

Tuesday, 30 July

12-2 p.m. |

  • P126: Observed vs. Predicted effects of Protein Binding: Improving In Vivo Predictions of Hepatic Clearance, Intracellular Concentration and IC50 Values

Wednesday, 31 July

12:30-2:30 p.m.

  • P235: In Vitro Development of Folate Transport And Endocytosis By Proton-coupled Folate Transporter (PCFT), Reduced Folate Carrier (RFC), and Folate Receptor α (FRα) in a Transwell System

BioIVT ADME-TOX experts will be available to answer questions at booth #301. Booth visitors will also have the opportunity to enter to win “Experimental Cholestasis Research” a new textbook co-authored by Dr. Brouwer. This book, which was edited by Mathieu Vinken, is a compilation of pertinent protocols for the experimental study of cholestasis.

Further information about this ISSX conference is available at


Media Contact Information: 

Lisa Osborne

Founder and CEO

Phone: (206) 992-5245